DelveInsight’s, “Anti-CD20 Antibody Pipeline Insight, 2023,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Anti-CD20 Antibody pipeline landscape. It covers the Anti-CD20 Antibody pipeline drug profiles, including Anti-CD20 Antibody clinical trials and nonclinical stage products. It also covers the Anti-CD20 Antibody pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Anti-CD20 Antibody pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Anti-CD20 Antibody clinical trials studies, Anti-CD20 Antibody NDA approvals (if any), and product development activities comprising the technology, Anti-CD20 Antibody collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Anti-CD20 Antibody Pipeline Insight Report
To explore more information on the latest breakthroughs in the Anti-CD20 Antibody Pipeline treatment landscape of the report, click here @ Anti-CD20 Antibody Pipeline Outlook
Anti-CD20 Antibody Overview
CD20 is a 33- to 37-kDa non-glycosylated phosphoprotein expressed on the surface of mature undifferentiated B-cells. Expression starts at the pre–B-cell stage, and persists until terminal differentiation into plasma cells. This pattern, together with consistent and high levels of expression of CD20 on malignant B-cells, makes CD20 a therapeutic target. CD20 protein consists of four hydrophobic transmembrane domains, one intracellular and two extracellular domains (large and small loops) with both N- and C- termini residing within the cytosol. Expression of CD20 antigen by the most of transformed B cells is believed to be the driving force for targeting this molecule by using anti-CD20 monoclonal antibodies. Anti-CD20 monoclonal antibodies (mAbs) are used to achieve B cell depletion, and were initially developed to treat B cell proliferative disorders, including non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Use of anti-CD20 therapy is vastly practiced to treat diseases with a high expression of CD20 antigen. Anti-CD20 antibodies are one of the most successful and effective antibodies which have employed in treatment of a wide range of diseases including cancer and immune related disorders.
Latest Breakthroughs/News of the Anti-CD20 Antibody Treatment Landscape
For further information, refer to the detailed Anti-CD20 Antibody Unmet Needs, Anti-CD20 Antibody Market Drivers, and Anti-CD20 Antibody Market Barriers, click here for Anti-CD20 Antibody Ongoing Clinical Trial Analysis
Anti-CD20 Antibody Emerging Drugs Profile
Ublituximab (TG-1101) is an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. When ublituximab binds to the B-cell it triggers a series of immunological reactions (including antibody-dependent cellular cytotoxicity [ADCC] and complement dependent cytotoxicity [CDC]), leading to destruction of the cell. TG Therapeutics completes the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) requesting approval of ublituximab, the Company’s investigational glycoengineered anti-CD20 monoclonal antibody as a treatment for patients with chronic lymphocytic leukemia (CLL). The U.S. FDA previously granted Fast Track designation to the combination of ublituximab and umbralisib (U2) for the treatment of adult patients with CLL and orphan drug designation for ublituximab in combination with umbralisib for the treatment of CLL.
Glofitamab (also known as RO7082859, RG6026) is an investigational, full-length, CD20- and CD3-targeting T-cell bispecific antibody that is designed to redirect T cells to engage and eliminate malignant B cells. Glofitamab is designed to bind to CD20, a B-cell surface protein expressed in a majority of B-cell malignancies, while simultaneously binding to CD3, a component of the TCR on the surface of T cells. A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin is underway in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Anti-CD20 Antibody Pipeline Therapeutic Assessment
There are approx. 20+ key companies which are developing the therapies for Anti-CD20 Antibody. The companies which have their Anti-CD20 Antibody drug candidates in the most advanced stage, i.e. Preregistration include, TG therapeutics.
Request a sample and discover the recent advances in Anti-CD20 Antibody Ongoing Clinical Trial Analysis and Medications, click here @ Anti-CD20 Antibody Treatment Landscape
Scope of the Anti-CD20 Antibody Pipeline Report
Dive deep into rich insights for drugs for Anti-CD20 Antibody Market Drivers and Anti-CD20 Antibody Market Barriers, click here @ Anti-CD20 Antibody Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Anti-CD20 Antibody Mergers and acquisitions, Anti-CD20 Antibody Licensing Activities @ Anti-CD20 Antibody Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NV 89107Country: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
